Pluri's Mounting Losses Raise Going Concern Doubts Amid Cash Burn

TL;DR

**PLUR is burning cash faster than it can innovate, making it a high-risk bet on a turnaround that looks increasingly unlikely.**

AI Summary

Pluri Inc. reported a net loss of $6.132 million for the three months ended September 30, 2025, a slight increase from the $6.036 million net loss in the same period last year. Revenue decreased marginally to $316 thousand from $326 thousand year-over-year. The company's gross profit declined significantly from $200 thousand in Q3 2024 to $115 thousand in Q3 2025, primarily due to an increase in cost of revenues from $126 thousand to $201 thousand. Research and development expenses, net, rose to $3.931 million from $2.889 million, reflecting increased investment in its cell-based technology platform. Pluri Inc. faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $448.905 million and a total shareholders' deficit of $11.360 million as of September 30, 2025. Cash balances totaled $16.393 million, down from $22.095 million at June 30, 2025. A critical risk is the $27.541 million EIB Loan due June 1, 2026, for which restructuring discussions are ongoing with no certainty of outcome. The strategic outlook hinges on securing additional capital, licensing agreements, CDMO services, and non-dilutive funding.

Why It Matters

Pluri Inc.'s deepening financial distress, evidenced by a $6.132 million net loss and a $11.360 million shareholders' deficit, signals significant risk for investors. The company's inability to generate sufficient revenue to cover escalating R&D costs and its reliance on external financing for survival put its long-term viability in question. For employees, this raises job security concerns, while customers and the broader market may see delays or discontinuation of its cell-based technology products. In a competitive biotech landscape, Pluri's liquidity issues could hinder its ability to innovate and commercialize, potentially ceding market share to better-capitalized rivals.

Risk Assessment

Risk Level: high — Pluri Inc. explicitly states it has an "accumulated deficit of approximately $448,905" and "incurred recurring operating losses and negative cash flows from operating activities since inception." Furthermore, management estimates the company "does not have sufficient resources to meet its operating obligations for at least twelve months from the issuance date of these interim unaudited condensed consolidated financial statements," raising "substantial doubt about the Company's ability to continue as a going concern."

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in PLUR. The company's explicit going concern warning, coupled with increasing losses and a critical EIB loan repayment due in June 2026, indicates a high probability of further share price depreciation or even bankruptcy if new funding isn't secured.

Financial Highlights

debt To Equity

N/A

revenue

$316K

operating Margin

N/A

total Assets

$33.672M

total Debt

$27.541M

net Income

-$6.132M

eps

N/A

gross Margin

36.4%

cash Position

$16.393M

revenue Growth

-3.1%

Key Numbers

• $6.132M — Net Loss (Increased from $6.036M in Q3 2024)
• $316K — Revenues (Decreased from $326K in Q3 2024)
• $115K — Gross Profit (Decreased from $200K in Q3 2024)
• $3.931M — Net Research and Development Expenses (Increased from $2.889M in Q3 2024)
• $448.905M — Accumulated Deficit (As of September 30, 2025)
• $11.360M — Total Shareholders' Deficit (As of September 30, 2025)
• $5.428M — Net Cash Used for Operating Activities (Increased from $4.064M in Q3 2024)
• $16.393M — Total Cash Balances (As of September 30, 2025, down from $22.095M at June 30, 2025)
• $27.541M — EIB Loan Balance (Due June 1, 2026, and classified as short-term liability)
• 9,253,897 — Common Shares Outstanding (As of November 11, 2025)

Key Players & Entities

• Pluri Inc. (company) — Registrant and biotechnology company
• European Investment Bank (company) — Lender for the EIB Loan
• Nasdaq Capital Market (regulator) — Exchange where PLUR common shares trade
• Tel-Aviv Stock Exchange (regulator) — Exchange where PLUR common shares trade
• U.S. Food and Drug Administration (regulator) — Regulatory body for manufacturing facility registration
• Pluri-Biotech Ltd. (company) — Wholly owned subsidiary of Pluri Inc.
• Ever After Foods Ltd. (company) — Majority-owned subsidiary of Pluri-Biotech Ltd.
• National Institute of Allergy and Infectious Diseases (company) — Participant in R&D funding
• Israeli Innovation Authority (company) — Participant in R&D funding
• Horizon Europe (company) — Participant in R&D funding

FAQ

Risk Factors

• Going Concern and EIB Loan Maturity [high — financial]: Pluri Inc. faces substantial doubt about its ability to continue as a going concern due to a significant accumulated deficit of $448.905 million and a total shareholders' deficit of $11.360 million as of September 30, 2025. A critical risk is the $27.541 million EIB Loan due June 1, 2026, which is classified as a short-term liability. Restructuring discussions are ongoing, but there is no certainty of a favorable outcome, posing a significant liquidity challenge.
• Declining Revenue and Gross Profit [high — financial]: Revenue decreased marginally to $316 thousand in Q3 2025 from $326 thousand in Q3 2024. More concerning is the significant decline in gross profit from $200 thousand to $115 thousand year-over-year, driven by an increase in the cost of revenues from $126 thousand to $201 thousand. This indicates deteriorating operational efficiency or pricing pressures.
• Increasing R&D Expenses and Cash Burn [medium — financial]: Research and development expenses, net, rose substantially to $3.931 million in Q3 2025 from $2.889 million in Q3 2024, reflecting increased investment in its cell-based technology platform. This, coupled with a net loss of $6.132 million, contributes to a net cash used for operating activities of $5.428 million, an increase from $4.064 million in the prior year's quarter.
• Deteriorating Cash Position [high — financial]: The company's cash balance has decreased to $16.393 million as of September 30, 2025, down from $22.095 million at June 30, 2025. This reduction in liquidity, combined with the significant upcoming EIB loan maturity and ongoing operational losses, heightens financial risk.
• Dependence on Future Capital and Agreements [high — operational]: Pluri Inc.'s strategic outlook is heavily dependent on securing additional capital, successful licensing agreements, obtaining CDMO services, and securing non-dilutive funding. The failure to achieve any of these critical objectives could severely impact the company's ability to fund its operations and development plans.
• Evolving Accounting Standards [low — regulatory]: The company is evaluating new accounting standards such as ASU 2025-05 (Credit Losses) and ASU 2025-07 (Derivatives and Hedging). While early adoption is permitted, the impact on financial statements is not yet determined, introducing potential future accounting complexities.

Industry Context

Pluri Inc. operates in the biotechnology sector, specifically focusing on cell-based technologies. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The competitive landscape includes established pharmaceutical companies and numerous startups vying for innovation and market share. Trends include advancements in regenerative medicine, personalized therapies, and sustainable food production, areas where Pluri Inc. is attempting to position itself.

Regulatory Implications

The biotechnology sector is heavily regulated by bodies like the FDA (in the US) and EMA (in Europe). Pluri Inc.'s cell-based technologies will require rigorous clinical trials and regulatory approvals before commercialization, which are costly and time-consuming. Failure to meet stringent regulatory standards can lead to significant delays or outright rejection of products.

What Investors Should Do

1. Monitor EIB Loan Restructuring Progress
2. Evaluate Capital Raising Efforts
3. Analyze R&D Investment Returns
4. Assess Revenue and Gross Margin Trends

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing a net loss of $6.132M, revenue of $316K, and a shareholders' deficit of $11.360M.
• 2026-06-01: EIB Loan Maturity — Critical short-term liability of $27.541M comes due, posing a significant refinancing or repayment risk.
• 2025-11-11: Common Shares Outstanding Reported — Indicates the current equity structure with 9,253,897 common shares outstanding.

Glossary

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income or capital contributions. (Indicates the company has historically operated at a loss, contributing to its going concern issues.)

Shareholders' Deficit

Occurs when a company's total liabilities exceed its total assets, resulting in a negative equity position. (Highlights Pluri Inc.'s negative net worth, a key indicator of financial distress.)

EIB Loan

A loan provided by the European Investment Bank. (Represents a significant short-term debt obligation for Pluri Inc. that requires urgent attention.)

CDMO

Contract Development and Manufacturing Organization. A company that provides services for drug development and manufacturing. (Pluri Inc. aims to generate revenue through CDMO services, indicating a potential diversification of its business model.)

Non-dilutive funding

Funding that does not require the company to issue new equity, thus not reducing the ownership percentage of existing shareholders. (Pluri Inc. is seeking this type of funding to avoid further dilution, which is a common concern for investors in early-stage or struggling companies.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The auditor's statement about substantial doubt regarding Pluri Inc.'s ability to continue as a going concern is a major red flag for investors.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Pluri Inc. has seen a slight decrease in revenue from $326 thousand to $316 thousand, alongside a more significant drop in gross profit from $200 thousand to $115 thousand. Net losses have widened slightly from $6.036 million to $6.132 million. A key concern is the substantial increase in R&D expenses, from $2.889 million to $3.931 million, contributing to higher cash burn. New risks include the classification of the EIB loan as a short-term liability and the ongoing uncertainty surrounding its restructuring, exacerbating the existing going concern doubts.

Key Financial Figures

• $0.00001 — ch registered Common Shares, par value $0.00001 PLUR The Nasdaq Capital Market Securi
• $1 — it $ 33,672 $ 38,683 (*) Less than $1 The accompanying notes are an integra

Filing Documents

• ea0263501-10q_pluri.htm (10-Q) — 469KB
• ea026350101ex10-1_pluri.htm (EX-10.1) — 91KB
• ea026350101ex31-1_pluri.htm (EX-31.1) — 11KB
• ea026350101ex31-2_pluri.htm (EX-31.2) — 11KB
• ea026350101ex32-1_pluri.htm (EX-32.1) — 4KB
• ea026350101ex32-2_pluri.htm (EX-32.2) — 4KB
• 0001213900-25-109174.txt ( ) — 3762KB
• plur-20250930.xsd (EX-101.SCH) — 32KB
• plur-20250930_cal.xml (EX-101.CAL) — 36KB
• plur-20250930_def.xml (EX-101.DEF) — 160KB
• plur-20250930_lab.xml (EX-101.LAB) — 327KB
• plur-20250930_pre.xml (EX-101.PRE) — 177KB
• ea0263501-10q_pluri_htm.xml (XML) — 312KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of September 30, 2025 U.S. DOLLARS IN THOUSANDS (Unaudited) INDEX Page Interim Condensed Consolidated Balance Sheets (Unaudited) 2 Interim Condensed Consolidated Statements of Operations (Unaudited) 4 Interim Condensed Consolidated Statements of Changes in Shareholders' Deficit (Unaudited) 5 Interim Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Interim Condensed Consolidated Financial Statements (Unaudited) 7 1 PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Note September 30, 2025 June 30, 2025 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 4,259 $ 5,895 Short-term bank deposits 10,797 14,718 Restricted cash 428 422 Customer receivables 294 236 Prepaid expenses and other current assets 1,143 824 Total current assets 16,921 22,095 LONG-TERM ASSETS: Restricted bank deposits 909 879 Severance pay fund 654 610 Property and equipment, net 1,764 1,823 Intangible assets, net 3 2,748 2,793 Goodwill 3,136 3,136 Operating lease right-of-use asset 6,753 6,900 Other long-term assets 787 447 Total long-term assets 16,751 16,588 Total assets $ 33,672 $ 38,683 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Note September 30, 2025 June 30, 2025 LIABILITIES AND SHAREHOLDERS' DEFICIT CURRENT LIABILITIES Trade payables $ 877 $ 866 Accrued expenses 884 1,178 Operating lease liability 673 659 Accrued vacation and recuperation 764 859 Advances from customers 105 148 Loa

financial statements disclosures

financial statements disclosures. ASU No. 2025-05 - "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets", or ASU 2025-05: In July 2025, the FASB issued ASU 2025-05. This amendment introduces a practical expedient for the application of the current expected credit loss model to current accounts receivable and contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. ASU No. 2025-07 - "Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract", or ASU 2025-07: In September 2025, the FASB issued ASU 2025-07, which refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration under ASC 606. This update is effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods, with early adoption permitted. Entities may apply the amendments prospectively to new contracts or retrospectively with a cumulative-effect adjustment. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. NOTE 3: - INTANGIBLE ASSETS, NET Three months ended September 30, 2025 Cost: Cocoa cell growth and application platform $ 2,685 Ability to develop additional applications 138 Total cost 2,823 Accumulated amortization: Cocoa cell growth and application platform 75 Ability to develop additional applications - Total accumulated amortization 75 Intangible assets, net $ 2,748 Amortizat

View Full Filing

View this 10-Q filing on SEC EDGAR